Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc is strategically positioned in the clinical-stage pharmaceutical sector, focusing on complex treatments for cancer, particularly targeting recurrent glioblastoma and leptomeningeal metastases. The company's candidate, rhenium (186Re) obisbemeda, has shown promising potential for reducing healthcare costs related to leptomeningeal metastases by approximately 40%, enhancing its value proposition to payers and health systems amid a challenging treatment landscape. Additionally, the FDA's constructive feedback for accelerated approval pathways for Reyobiq underscores the significant unmet medical need in these indications, potentially driving increased adoption and reimbursement opportunities for the company.

Bears say

Plus Therapeutics Inc. faces significant financial challenges, as indicated by its recent downgrade and lowered price target, reflecting a potentially strained capital market environment linked to a reverse stock split. The company reported a substantial operating loss of $15.3 million for the full year 2025, coupled with a net loss of $22.4 million, raising concerns about its financial sustainability and operational efficiency. Despite ending 2025 with $13.1 million in cash and investments, the continuity of funding and the impact of upcoming warrant exercises contribute to an uncertain outlook for the company's liquidity and overall financial health.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.